2026 H1 -tulosraportti
UUTTA
2 päivää sitten
‧45 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sitten"He who waits, waits, he who gets to see, gets to see" sings Prepple. TRMED will also be volatile going forward as the stock is still driven by events, news flow, hype and future results. That many secure profits, go in and out in the relatively short term, is also not surprising. In the coming week, we might as well see the 7-mark as the 5-mark. Technically, the stock is now at a crossroads. Support lies around 5.50–6.00, while 6.40–6.80 is the nearest resistance. A break of one of these areas will likely set the direction in the short term. Don't forget that TA can say something about timing and market sentiment, but in the long term the price must be defended by actual deliveries, results and cash flow. Familiarize yourself with the case and make your own assessments based on your own strategy and risk appetite. To quote yet another cool character: "Nobody knows if a stock is going to go up, down, sideways or in circles" Good luck on your journey, with or without TRMED in your luggage! "The road is the goal. Be bop a lu let us pray..."
·1 päivä sittenAnyone with good TA skills who, based on GAP analysis and/or Fibonacci, can draw some lines?
Do not wish to share my own analysis but, you can easily add Fibonacci retracement with TradingView's Fibonacci tool, they have most TA tools completely free, just that there is a limit to how many indicators you can have, but you can alternatively have that on Nordnet.
·2 päivää sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
·2 päivää sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.
2 päivää sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 H1 -tulosraportti
UUTTA
2 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten"He who waits, waits, he who gets to see, gets to see" sings Prepple. TRMED will also be volatile going forward as the stock is still driven by events, news flow, hype and future results. That many secure profits, go in and out in the relatively short term, is also not surprising. In the coming week, we might as well see the 7-mark as the 5-mark. Technically, the stock is now at a crossroads. Support lies around 5.50–6.00, while 6.40–6.80 is the nearest resistance. A break of one of these areas will likely set the direction in the short term. Don't forget that TA can say something about timing and market sentiment, but in the long term the price must be defended by actual deliveries, results and cash flow. Familiarize yourself with the case and make your own assessments based on your own strategy and risk appetite. To quote yet another cool character: "Nobody knows if a stock is going to go up, down, sideways or in circles" Good luck on your journey, with or without TRMED in your luggage! "The road is the goal. Be bop a lu let us pray..."
- ·1 päivä sittenAnyone with good TA skills who, based on GAP analysis and/or Fibonacci, can draw some lines?Do not wish to share my own analysis but, you can easily add Fibonacci retracement with TradingView's Fibonacci tool, they have most TA tools completely free, just that there is a limit to how many indicators you can have, but you can alternatively have that on Nordnet.
- ·2 päivää sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
- ·2 päivää sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.2 päivää sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
2026 H1 -tulosraportti
UUTTA
2 päivää sitten
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten"He who waits, waits, he who gets to see, gets to see" sings Prepple. TRMED will also be volatile going forward as the stock is still driven by events, news flow, hype and future results. That many secure profits, go in and out in the relatively short term, is also not surprising. In the coming week, we might as well see the 7-mark as the 5-mark. Technically, the stock is now at a crossroads. Support lies around 5.50–6.00, while 6.40–6.80 is the nearest resistance. A break of one of these areas will likely set the direction in the short term. Don't forget that TA can say something about timing and market sentiment, but in the long term the price must be defended by actual deliveries, results and cash flow. Familiarize yourself with the case and make your own assessments based on your own strategy and risk appetite. To quote yet another cool character: "Nobody knows if a stock is going to go up, down, sideways or in circles" Good luck on your journey, with or without TRMED in your luggage! "The road is the goal. Be bop a lu let us pray..."
- ·1 päivä sittenAnyone with good TA skills who, based on GAP analysis and/or Fibonacci, can draw some lines?Do not wish to share my own analysis but, you can easily add Fibonacci retracement with TradingView's Fibonacci tool, they have most TA tools completely free, just that there is a limit to how many indicators you can have, but you can alternatively have that on Nordnet.
- ·2 päivää sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
- ·2 päivää sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.2 päivää sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt